Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

February 9, 2026

Study Completion Date

June 22, 2026

Conditions
Obesity and Overweight
Interventions
DRUG

GZR18

GLP-1

DRUG

Tirzepatide

Active Comparator

Trial Locations (20)

21045

KUR Research @ Columbia Site Network, Columbia

32216

East Coast Institute for Research - ECIR Jacksonville (Southside), Jacksonville

East Coast Institute for Research ECIR Jacksonville (Headquarters) University, Jacksonville

33126

Clever Medical Research - PCRS Network, Miami

33460

3Sync Research - PCRS Network, Lake Worth

35022

KUR Research - Trinity @ Bessemer, AL Site Network, Bessemer

35042

KUR Research - Trinity @ Centreville Site Network, Centreville

43212

ERG - Ohio Clinical Trials, Columbus

45212

Populace Health, LLC - CTI Clinical Research Center, Cincinnati

72211

ERG - Woodland Int'l Research Group, Little Rock

72758

ERG - Woodland Research Northwest, Rogers

77493

Clinvax Katy Research Center, Katy

78229

Endeavor Clinical Trials, San Antonio

78704

Elligo Clinical Research Center - Austin, Austin

89128

Populace Health, LLC - Vector Clinical Trials, Las Vegas

90815

Ark Clinical Research Ark-Long Beach, Long Beach

91763

Populace Health, LLC - Catalina Research Institute, Montclair

92708

Ark Clinical Research Ark-Fountain Valley, Fountain Valley

95350

Clinedge - Central Valley Research, LLC, Modesto

01103

Populace Health, LLC - Elixia SISU, Springfield

All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY

NCT06737042 - Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | Biotech Hunter | Biotech Hunter